Intravenous formulation of rifabutin based on PLGA nanoparticles: in-vivo performance

摘要

Encapsulation of rifabutin (RB) in PLGA nanoparticles (NP) enables the intravenous administration of this poorly soluble antibiotic. The nanoparticle-bound RB appeared to be more effective against M. tuberculosis infection in mice but induced hepato- and splenotoxicity.